Veracyte Biopharma Services

Veracyte Inc. is a molecular diagnostics company based in San Francisco, California, founded in 2006.

With around 676 employees, Veracyte focuses on developing and commercializing genomic tests that enhance cancer diagnosis and treatment planning. The company has a market capitalization of $2.74 billion and has positively impacted over 800,000 patients through its innovative genomic tests. Veracyte's product portfolio includes the Afirma Genomic Sequencing Classifier for thyroid nodule analysis, the Percepta Bronchial Genomic Classifier for lung cancer diagnosis, the Envisia Genomic Classifier for idiopathic pulmonary fibrosis, the Prosigna Breast Cancer Prognostic Gene Signature Assay, and the Decipher Prostate Metastatic Test. The company operates through testing services, product sales, and biopharmaceutical licensing. Veracyte is recognized for its employee-centric culture and has been certified as a Great Place to Work.